drugset
drugset / Trial / NCT01749098

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

NCT01749098 ↗

Phase 1 Completed 29 enrolled Biogen
RandomizedCrossoverDouble-blindBasic science

Summary

To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.

Timeline

Start
2012-12
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.25 mg Oral
Comparator Ketamine Small molecule 0.58 mg/kg Intravenous

Indications

schizophrenia